Acceso usuarios
* Two new antibiotics, tedizolid (Sivextro) and oritavancin (Orbactiv), were recently approved to treat serious skin and skin-structure infections.
* Tedizolid is given for six days either orally or intravenously. The most common adverse effects are nausea, headache, diarrhea, vomiting, and dizziness.
* Oritavancin is given as a single IV dose. The most common adverse effects are headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.
